Biohaven Ltd. (NYSE:BHVN) Stake Boosted by Stifel Financial Corp

Stifel Financial Corp increased its holdings in Biohaven Ltd. (NYSE:BHVN) by 0.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,509,261 shares of the company’s stock after purchasing an additional 28,684 shares during the period. Stifel Financial Corp owned approximately 0.06% of Biohaven worth $325,268,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in Biohaven by 5.6% during the third quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company’s stock valued at $311,142,000 after acquiring an additional 328,099 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Biohaven by 181.4% in the second quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock valued at $78,028,000 after buying an additional 1,449,000 shares during the period. Point72 Asset Management L.P. lifted its stake in Biohaven by 745.9% during the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock worth $74,969,000 after purchasing an additional 1,322,922 shares during the period. Armistice Capital LLC lifted its stake in Biohaven by 74.8% during the second quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock worth $48,489,000 after purchasing an additional 597,705 shares during the period. Finally, ARS Investment Partners LLC lifted its stake in Biohaven by 47.8% during the second quarter. ARS Investment Partners LLC now owns 940,512 shares of the company’s stock worth $32,645,000 after purchasing an additional 304,141 shares during the period. 88.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BHVN has been the subject of a number of research analyst reports. Leerink Partners lifted their target price on shares of Biohaven from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, September 23rd. William Blair raised shares of Biohaven to a “strong-buy” rating in a research report on Friday, August 30th. Sanford C. Bernstein lifted their price target on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 24th. Robert W. Baird boosted their price objective on shares of Biohaven from $58.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Finally, TD Cowen boosted their price objective on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Biohaven has a consensus rating of “Buy” and a consensus price target of $63.00.

Insider Activity at Biohaven

In related news, Director Gregory Bailey bought 5,000 shares of the stock in a transaction on Tuesday, September 24th. The shares were acquired at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the purchase, the director now owns 1,620,071 shares of the company’s stock, valued at approximately $71,590,937.49. The trade was a 0.31 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John W. Childs acquired 21,052 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the purchase, the director now directly owns 21,052 shares in the company, valued at approximately $999,970. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by insiders.

Biohaven Trading Up 5.4 %

Shares of NYSE:BHVN opened at $46.06 on Thursday. Biohaven Ltd. has a 12 month low of $26.80 and a 12 month high of $62.21. The stock has a market cap of $4.66 billion, a P/E ratio of -4.93 and a beta of 1.24. The company has a 50 day moving average of $49.65 and a 200 day moving average of $41.55.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). On average, equities analysts forecast that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.